Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: Functional magnetic resonance imaging (MRI) studies have shown that APOE ε2‐ and ε4‐carriers have similar patterns of blood‐oxygenation‐level‐dependent (BOLD) activation suggesting that we need to look beyond the BOLD signal to link APOE's effect on the brain to Alzheimer's disease (AD)‐risk. Methods: We evaluated APOE‐related differences in BOLD activation in response to a memory task, cerebrovascular reactivity using a CO 2‐inhalation challenge (CO 2‐CVR), and the potential contribution of CO 2‐CVR to the BOLD signal. Results: APOE ε4‐carriers had the highest task‐related hippocampal BOLD signal relative to non‐carriers. The largest differences in CO 2‐CVR were between ε2‐ and ε4‐carriers, with the latter having the lowest values. Genotype differences in CO 2‐CVR accounted for ∼70% of hippocampal BOLD differences between groups. Conclusion: Because CO 2‐CVR gauges vascular health, the differential effect of APOE in young adults may reflect a vascular contribution to the vulnerability of ε4‐carriers to late‐life pathology. Studies confirming our findings are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Early identification of changes in brain function in individuals at risk for AD is the key to developing interventional strategies and laying the groundwork for clinical population studies [50].”
BackgroundProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“Conversely, the ε2 allele has been associated with lower risk of AD-related pathology, and therefore is believed to confer protection [6].”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“The ε4 allele is the best-established genetic risk factor for sporadic late-onset Alzheimer’s disease (AD) [2], and it has been shown to increase the prevalence and lower the age of onset of AD in a gene-dose dependent way [3].”
BackgroundApolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613 · cited 3×
“Familiar” memory-encoding paradigm performed using Presentation software [13] (see Supplementary Materials).”
BackgroundMethodInfluentialSelf-citationPatterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328 · cited 1×
“Our primary targets were the medial temporal lobes and the hippocampi, because these are the earliest brain regions to show pathologic signs of AD and are modulated by APOE [25].”
BackgroundApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 2×
“Although the direct effect of the ε2 allele on brain metabolism has not yet been investigated, PET studies reporting reduced glucose metabolism in young ε4-carriers relative to ε3-homozygotes [10] seem to bolster this interpretation.”
BackgroundLongitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Apolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease
Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2152 · Cited by 263
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Sun, Y., Wu, S., Bu, G., Onifade, M. K., Patel, S. N., LaDu, M. J., Fagan, A. M., & Holtzman, D. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03261.1998 · Cited by 213
Lin, A.-L., Fox, P. T., Hardies, J., Duong, T. Q., & Gao, J.-H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909711107 · Cited by 213 · cited 3×
“It is in fact possible that fluctuations in vasodilation and/or CBF that occur as a result of task-related metabolic demand are regulated by different mechanisms than those induced by variations in the PaCO2 [41].”
BackgroundSuri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183
Self-citationFilippini, N., Rao, A., Wetten, S., Gibson, R. A., Borrie, M., Guzman, D., Kertesz, A., Loy-English, I., Williams, J., Nichols, T., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.003 · Cited by 143 · cited 1×
“Neuroimaging studies have reported reduced hippocampal volumes [8,9] andglucosemetabolism [10] in bothADpatients and healthy ε4-carriers relative to noncarriers.”
BackgroundSelf-citation
Cited by
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation
Claassen, J. A. H. R., Thijssen, D. H. J., Panerai, R. B., & Faraci, F. M. (2021) · Physiological Reviews · doi:10.1152/physrev.00022.2020 · Cited by 915
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
“Functional changes such as impaired cerebrovascular reactivity that reflects diminished vasodilation of cerebral vessels in response to a CO 2 inhalation challenge can be measured using either blood oxygenation level dependent (BOLD) functional MRI [48,49] or arterial spin labeling (ASL) [26] at the tissue level, or t…”
Influential
Metadata
- Authors
- Suri, S., Mackay, C. E., Kelly, M. E., Germuska, M., Tunbridge, E. M., Frisoni, G. B., Matthews, P. M., Ebmeier, K. P., Bulte, D. P., & Filippini, N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-08-23
- Volume
- 11
- Issue
- 6
- Pages
- 648
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2017420974
- Cited by
- 112
- References
- 16
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.